Smart Care Based on Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-Center Randomized Controlled Trial.

Source: Jeong, J. Y., et al. 2018 - Pubmed ID: 29341843

Setting: South Korea, 4 university hospitals

Study design:



Follow up: 24 weeks

Patient group:

Sample size:

Total: 338 (299)

Telemonitoring: 113 (99)

Telemedicine: 112 (99)

CG: 113 (101)


Inclusion criteria:

  • Diabetes type 2
  • HbA1c ranging from 7-11%
Type of technology:

Home monitoring

  • Web enabled computer
  • Specific software
  • Glucometer
  • Body composition analyzer

Video consultation


Intervention: Tele monitoring – Pt. performs measures on clinical data by using home monitoring equipment. Reports to endocrinologist after 8, 16, 24 weeks on scheduled outpatient appointment. Telemedicine – Instead of outpatient visits on hospital, patients contacted physicians from their equipment.


Duration: 24 weeks

Add on:


Control group: Conventional care

Clinical effect/ Patient safety:

Clinical effect:

  • HbA1c →
  • HbA1c target (≤7%) →
  • Cholesterol →
  • Weight →
  • BMI →
  • Blood pressure →

Patient safety: Adverse events were reported in 33, 30 and 23 patients in the control, telemonitoring, and telemedicine groups, respectively, and adverse events related to complications of diabetes in seven, seven, and three patients, respectively

Patient experiences/ Staff experiences:

Patient experiences: NA


Staff experiences: NA

Costs and organization:



  • Computer
  • Glucometer


Staff resources

  • Online communication with patients


Health care utilization: NA

Scroll to Top


“↑”: Statistically significant increase

“↓”: Statistically significant decrease

“→”: Statistically insignificant (no difference)